A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (ARISE2)

Balance Therapeutics

Status and phase

Unknown

Phase 2

Conditions

Idiopathic Hypersomnia

Treatments

Drug: Pentetrazol (PTZ)

Drug: Placebo oral capsule

Study type

Interventional

Funder types

Industry

Identifiers

NCT03542851

BTD-001 IH202

Details and patient eligibility

About

This is a randomized, placebo-controlled, double-blind, crossover study of oral BTD-001 in adults with Idiopathic Hypersomnia.

Full description

This is a randomized, placebo-controlled, double-blind, crossover study of oral BTD-001 in adults with Idiopathic Hypersomnia (IH). The objectives of this study are two-fold: 1) To evaluate the efficacy of BTD-001 in subjects with IH as reflected by changes in cognitive, sleep, functional, and quality-of-life measures and 2) To characterize the safety and tolerability of oral BTD-001 administered to subjects with IH.

Enrollment

80 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Males or Females age 18 to 70 years old
Onset of hypersomnia between age 10 and 30 years of age
An Epworth Sleepiness Scale score of greater than or equal to 11
Able to comply with requirements for concomitant medications and consumption of caffeine, alcohol, tobacco and nicotine (if on stimulants, agree to adhere to stable regimen throughout the trial)
Females with a negative pregnancy test AND who are non-lactating
Sexually active females of childbearing potential must be willing to use a highly effective method of birth control
Sexually active males must have a vasectomy or use condoms

Exclusion criteria

History of any disorder causing hypersomnia other than IH
Evidence of circadian-rhythm disorder
Sleep apnea syndrome
Use of CPAP
Obese subjects with BMI greater than or equal to 35kg/m2
History of or current seizure disorder or history of syncope, unexplained loss of consciousnesses or seizure in the past 3 years as well as any past history of benzodiazepine and/or barbiturate and/or alcohol-related withdrawal seizures
Columbia-Suicide Severity Rating Scale (C-SSRS) findings consistent with significant history of or current suicidal ideation or behavior
Subjects who fail to wash out medications for IH or any other prohibited medications
Positive toxicology screen test during the Screening or Baseline Visits.
Clinically significant abnormal findings from physical, electrocardiogram (ECG) or laboratory assessments at Screening
History of or current significant pulmonary, cardiac, neurological or psychiatric disease, substance dependence, porphyria, malignancy (with exception of local cutaneous squamous or basal cell carinomas or local cervical squamous cell carcinoma resolved after resection) or hypothyroidism (unless euthyroid at Screening Visit and treated with a stable dose of medication for at least 3 months prior to the Baseline Visit).
Participation in a clinical drug trial within 4 weeks of Screening Visit